Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Significant Growth in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 105,100 shares, a growth of 317.1% from the March 31st total of 25,200 shares. Currently, 25.0% of the shares of the company are short sold. Based on an average daily volume of 497,100 shares, the days-to-cover ratio is presently 0.2 days.

Allarity Therapeutics Price Performance

Shares of NASDAQ ALLR traded up $0.03 during mid-day trading on Friday, reaching $1.46. 188,287 shares of the company traded hands, compared to its average volume of 1,612,238. Allarity Therapeutics has a fifty-two week low of $1.27 and a fifty-two week high of $415.92. The stock has a fifty day simple moving average of $5.57 and a 200-day simple moving average of $8.80.

Institutional Trading of Allarity Therapeutics

An institutional investor recently bought a new position in Allarity Therapeutics stock. Armistice Capital LLC acquired a new stake in Allarity Therapeutics, Inc. (NASDAQ:ALLR) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 261,000 shares of the company’s stock, valued at approximately $195,000. Armistice Capital LLC owned about 9.56% of Allarity Therapeutics at the end of the most recent quarter. 11.53% of the stock is owned by institutional investors and hedge funds.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.